Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.

By Richard A. Miller, D. Harrison, C. M. Astle, Joseph A. Baur, A. Boyd, R. Cabo, Elizabeth Fernandez, K. Flurkey, M. Javors, J. Nelson and 8 more. The journals of gerontology. Series A, Biological sciences and medical sciences, 2011

902 citations recorded by the source corpus.

Subfields: Aging, Geriatrics and Gerontology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a2b90af0ff892a6971ab39e994bbc66280906d35

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Aging

In Geriatrics and Gerontology

In Molecular Biology

Citations in the corpus

Regulation of mTORC1 and its impact on gene expression at a glance (2013, background): “As a proof-ofconcept, a reduction in mTORC1 activity has been shown to promote life extension in mice (Harrison et al., 2009; Lamming et al., 2012; Miller et al., 2011) and to reduce the severity of neurodegeneration in several models (reviewed by Sarkar and Rubinsztein, 2008).”
Measuring biological aging in humans: A quest (2019, background): “Rapamycin analogs that selectively target TORC1, which should have less side effects, have been proposed for treatment of diseases of aging (Arriola Apelo & Lamming, 2016; Bjedov et al., 2010; Chi et al., 2015; El-Chemaly et al., 2017; Miller et al., 2010).”
mTOR signaling in growth control and disease (2012, positive): “In mice, rapamycin-mediated life extension is not associated with change in disease patterns or causes of death (Harrison et al., 2009; Miller et al., 2011).”
Resveratrol and health--a comprehensive review of human clinical trials. (2011, background): “Recent data suggest that resveratrol does not extend lifespan in healthy mice or in a model of premature aging [9], but does appear to delay or attenuate many agerelated changes and prevent early mortality in obese animals [10–12].”
Senescence and the SASP: many therapeutic avenues (2020, background): “The antidiabetic drug metformin alleviates a number of age-related conditions in experimental animal models and humans and inhibits multiple proinflammatory SASP factors by blocking NFκB nuclear translocation (Moiseeva et al. 2013).”
The Ratio of Macronutrients, Not Caloric Intake, Dictates Cardiometabolic Health, Aging, and Longevity in Ad Libitum-Fed Mice (2014, background): “Moreover, inhibition of mTOR with rapamycin increases lifespan in mice fed a standard diet and represents evidence of pharmacological life extension in normal mammals (Harrison et al., 2009; Miller et al., 2011).”
mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype (2015, neutral): “The 14 ppm dose has previouslybeenshowntoextendlifespanwhenstartedat9orat20monthsofage 21,56 .”
Metformin as a Tool to Target Aging (2016, positive): “When rapamycin is administered late in life, it extends lifespan (Harrison et al., 2009; Miller et al., 2011), slows aging in a dose-dependent manner, shows differential effects by sex (Wilkinson et al., 2012), and is synergistic with metformin.”